SVF Vaccines to Merge with Novakand Pharma in SEK 55M Reverse Acquisition
Event summary
- SVF Vaccines will be acquired by Novakand Pharma in a reverse acquisition valued at SEK 55 million, with SVF shareholders receiving 66.7% of the combined company.
- The transaction is subject to approvals from Novakand’s extraordinary general meeting, Nasdaq, and the Inspectorate of Strategic Products, with completion targeted for Q1 2026.
- The merged entity will focus on SVF’s vaccine development while retaining Novakand’s fractalkine program, with a planned SEK 30 million phase 1 study for SVF-001.
- Karolinska Development, SVF’s largest shareholder with 33% ownership, will support the capital raise for the phase 1 study.
The big picture
This reverse acquisition reflects a broader trend in biotech where smaller, innovative firms merge with listed entities to accelerate development and access capital. The SEK 55 million deal underscores the strategic value of SVF’s vaccine technology, particularly as Karolinska Development leverages its network to support the next phase of clinical trials. The transaction also highlights the regulatory hurdles inherent in biotech M&A, where approvals from exchanges and strategic product inspectors can dictate success or failure.
What we're watching
- Regulatory Approval
- Whether the transaction receives timely approval from Nasdaq and the Inspectorate of Strategic Products, as delays could impact the planned phase 1 study timeline.
- Capital Raise
- The success of the planned capital raise to fund the SEK 30 million phase 1 study, which is critical for the combined company’s short-term viability.
- Strategic Focus
- How the merged entity balances SVF’s vaccine development with Novakand’s existing fractalkine program, and whether this dual focus creates operational efficiencies or conflicts.
Related topics